Skip to content
DataLookout
Menu

COMPACTNCT07926152

Exercise and Protein to Reduce Muscle Loss During GLP-1-Based Treatment in Type 2 Diabetes

StatusNot Yet Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change in Contractile Thigh Muscle Volume
Timeframe: Baseline to week 24

Secondary (19)

Percent Change in Contractile Thigh Skeletal Muscle Volume
Change in Body Weight
Change in Isometric Knee Extensor Strength
Change in Isometric Knee Flexor Strength
Change in 30-Second Chair Stand Test Performance
Show 14 moreShow less
Change in Usual Gait Speed
Change in Handgrip Strength
Change in Standing Balance
Change in Thigh Intramuscular Adipose Tissue Volume
Change in Visceral Adipose Tissue Volume
Change in Subcutaneous Adipose Tissue Volume
Change in Hepatic Lipid Content (¹H-MRS)
Change in Liver Proton Density Fat Fraction (MRI-PDFF)
Change in Fat Mass
Change in Fat-Free Mass
Change in Whole-Body Insulin Sensitivity
Change in Liver Stiffness
Change in Absolute Maximal Oxygen Uptake (VO2max)
Change in Relative Maximal Oxygen Uptake (VO2max)

Arms and interventions

Exercise and Protein SupplementationExperimental

Participants continue their GLP-1 receptor agonist therapy (semaglutide or tirzepatide) as prescribed by their treating physician and receive one standardized lifestyle counselling session on nutrition and physical activity at baseline. In addition, they take part in a 24-week supervised training program with three sessions per week at the study center, alternating between full-body resistance training, high-intensity interval training on a cycle ergometer, and a combined session. Training intensity is progressively increased and individually adjusted. Participants also take 25 g of whey protein isolate daily, directly after each training session or in the morning on training-free days.

Usual CareActive comparator

Participants continue their GLP-1 receptor agonist therapy (semaglutide or tirzepatide) as prescribed by their treating physician and receive one standardized lifestyle counselling session on nutrition and physical activity at baseline. They do not take part in the supervised training program and do not receive protein supplementation.

Behavioral: Supervised exercise training, Standardized lifestyle counseling

Dietary supplements: protein supplement

Sites

1 site in 1 country

  • German Diabetes CenterDüsseldorf, North Rhine-Westphalia, Germany